Combination Therapy for Pediatric Asthma Patients

Trial Objective

Combination Therapy for Pediatric Asthma PatientsOur researchers are trying to determine if a combination of fluticasone furoate (FF) and vilanterol (VI) is more effective than FF alone in improving lung function and symptoms such as coughing, wheezing, chest tightness and breathlessness in pediatric asthma patients.

FF (which is approved for treatment of asthma) is typically used to treat asthma in adults. This study is adding the use of VI (which is not currently approved for the treatment of asthma). The study also will determine the safety of the combination of FF and VI. Some participants will receive FF and VI, some others will receive FF alone. There is no placebo for this study.


New enrollment for this trial is temporarily paused

Who Can Participate

Children and teens ages 5 to 17 who have uncontrolled asthma and are receiving stable asthma therapy.

Age: 5-17    Gender: Any Gender

Estimated Time Commitment

7 visits up to 29 weeks

(1) a four-week period during when participants will receive a study medication called Fluticasone Propionate (FP), (2) a 24-week treatment period when participants will not know if they are receiving the study medication.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Michael White

Michael White

D Sundstrom

Dee Sundstrom

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

GlaxoSmithKline (GSK)

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at